SPL.AX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 02:10):

Stats
Today's Volume	139 014
Average Volume	340 681
Market Cap	55.63M
EPS	$0 ( 2024-02-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.75
ATR14	$0 (0.00%)

Starpharma Holdings Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Starpharma Holdings Ltd Financials

Annual	2023
Revenue:	$2.94M
Gross Profit:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Revenue:	$2.94M
Gross Profit:	$1.22M (41.60 %)
EPS:	$-0.0400

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

FY	2022
Revenue:	$4.68M
Gross Profit:	$1.91M (40.71 %)
EPS:	$-0.0400

Financial Reports:

No articles found.

Starpharma Holdings Ltd

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.